Biohaven's depression drug fails mid-stage trial, shares fall

Core Insights - Biohaven's experimental depression drug failed to meet the primary endpoint in a mid-stage trial, indicating ongoing challenges for the company in its drug development efforts [1] Company Summary - The recent trial setback adds to a series of difficulties faced by Biohaven this year, including other trial and regulatory issues [1]